These are the posts from the How we think section that have been tagged with Bristol-Myers Squibb.
To see all tags used in our posts, click here.
|24th August 2016
In this article, Associate Consultant Louis Perdios talks about the immunotherapy drug Opdivo and the daunting challenges faced by BMS after disappointing results. However the future for Opdivo may not be as bleak as it seems.